What is the consistency between the results of needle biopsy and prostatectomy specimen pathology results? A pilot study

Ömer Ozan YILDIZLI1, İbrahim ÜNTAN2*, Deniz DEMİRCİ3

1Department of Urology, Melikgazi Hospital, Kayseri, Turkey
2Department of Urology, Training and Research Hospital, Ahi Evran University, Kırşehir, Turkey
3Department of Urology, Faculty of Medicine, Erciyes University, Kayseri, Turkey

Background/aim: The aim of this study was to establish the relationship between the needle biopsy and the pathology result after radical prostatectomy administrated for prostate cancer.

Materials and methods: We retrospectively analyzed 67 patients who had undergone radical prostatectomy from 2016 to 2019. All surgeries and all biopsies were performed in the third author's urology department. Samples were collected through 12-core biopsy under local anesthesia. All specimens were studied in the pathology department of the third author's center. The results evaluated were needle biopsies' Gleason scores and prostatectomy specimens' Gleason scores.

Results: Inclusion criteria were not having any neo-adjuvant treatment and being treated with surgery after needle biopsy. Gleason scores obtained from needle biopsies and prostatectomy specimens were evaluated. The comparison revealed that 39% of the tumors were undergraded, 7% were overgraded, and 54% had exact scoring in needle biopsies and prostatectomy specimens according to the detailed Gleason scoring as primary and secondary metrics. The patients were grouped into five categories according to the ISUP 2014 prostate cancer grading system. The relationship was strong with 64% of results staying in the same group after the operation; nevertheless, the correlation remained weak based on the kappa coefficient.

Conclusion: The information obtained from the needle biopsy is not a strong herald of the pathological result. Urologists should have awareness of this restraint when utilizing the needle biopsy's Gleason score in decision making and treatment planning.

Key words: Accuracy, biopsy pathology, correlation, prostate cancer, prostatectomy pathology

1. Introduction
Clinical staging of the prostate cancer is essential in starting a therapy plan [1]. Transrectal ultrasound (TRUS)-guided prostate biopsy is a standard procedure for predicting postoperative pathological grade in many centers [2]. Clinical grades refer to prostate biopsy and are critical in patients who are candidates for radiotherapy or watchful waiting because these stages guide prognosis and treatment [3].

The accuracy of needle biopsy is inconclusive [4,5]. Magnetic resonance imaging (MRI)-guided prostate biopsy including MRI/ultrasound fusion biopsy is rapidly increasing with good accuracy [6,7]. On the other hand, repeat biopsy procedure and saturation biopsy methods can empower urologists to improve the accuracy [8,9]. Nevertheless, urologists still rely on 12-core needle biopsies because other methods are rare, require more personnel, and are more invasive. Therefore, we evaluated the correlation between the Gleason scores on biopsies and prostatectomy specimens in 67 patients who were diagnosed with prostate adenocarcinoma, had no neo-adjuvant treatment or radiotherapy, and had undergone radical prostatectomy (RP).

2. Materials and methods
The retrospective study was conducted in Erciyes University, Faculty of Medicine, Department of Urology. Sixty-seven patients who underwent RP for prostate adenocarcinoma in our center between 2016 and 2019 were enrolled. The patients' files, charts, and computerized data were collected, and the pathology results of needle biopsies and prostatectomy specimens, ages, and PSA levels before biopsies were noted. Pathology results were summarized including Gleason score as the primary and secondary grading in needle biopsies and prostatectomy specimens, border extension, and seminal vesicle invasion.

* Correspondence: ibrahimuntan@hotmail.com

1360
in prostatectomy specimen results as well. Patients were subjected to clinical tumor node metastasis classification for staging (Table 1). T-staging is mainly based on digital rectal examination (DRE), but transrectal ultrasonography (TRUS) or multiparametric MRI is also considered if performed. N-staging was mostly done with computed tomography (CT) and MRI. M-staging was mostly done with bone scan.

Patients were defined as localized and locally advanced prostate cancer according to the PSA level, Gleason score, and clinical staging. For surgical treatment, a life expectancy of at least 10 years is required. Active surveillance, radiotherapy, and radical prostatectomy options are offered to the patients in the localized group. Radiotherapy and radical prostatectomy options are offered to patients in the locally advanced group (Table 2). The patients in our study are patients who proceeded according to this scheme and finally decided and applied radical prostatectomy. A senior surgeon managed all the RPs and another experienced surgeon helped the senior surgeon.

All specimens were studied in our hospital's own pathology department by randomly assigned pathologists. Clinical information (e.g., age, DRE, PSA) was also included. A positive surgical margin was defined as the presence of cancerous tissue in contact with the inked surface of the prostatectomy specimen. Healthy tissue margins were considered negative margins. Some of the biopsy reports where the tumor was graded as good, moderate, or poor differentiation did not contain Gleason scores; thus, these documents were excluded from the study. No patient received radiotherapy or hormone therapy before RP. The Gleason grades were compared separately in biopsy and pathology groups as primary and secondary. The sums of Gleason scores were compared in biopsy and pathology groups. Grade groups in which the score totals correspond to International Society of Urological Pathology (ISUP) were also compared before and after RP (Table 3) [10].

Table 1. Clinical tumor node metastasis classification of prostate cancer.

| T- primary tumor |          |
|------------------|----------|
| TX               | Primary tumor cannot be assessed |
| T0               | No evidence of primary tumor |
| T1               | Tumor that is palpable and confined within the prostate |
| T1a              | Tumor incidental histological finding in 5% or less of tissue resected |
| T1b              | Tumor incidental histological finding in more than 5% of tissue resected |
| T1c              | Tumor identified by needle biopsy (e.g., because of elevated PSA) |
| T2               | Tumor that is palpable and confined within the prostate |
| T2a              | Tumor involves one half of one lobe or less |
| T2b              | Tumor involves more than half of one lobe, but not both lobes |
| T2c              | Tumor involves both lobes |
| T3               | Tumor extends through the prostatic capsule |
| T3a              | Extracapsular extension (unilateral or bilateral) |
| T3b              | Tumor invades seminal vesicle(s) |
| T4               | Tumor is fixed or invades adjacent structures other than seminal vesicles: external sphincter, rectum, levator muscles, and/or pelvic wall |

| N – regional (pelvic) lymph nodes |          |
|----------------------------------|----------|
| NX                               | Regional lymph nodes cannot be assessed |
| N1                               | No regional lymph node metastasis |
| N2                               | Regional lymph node metastasis |

| M - distant metastasis |          |
|------------------------|----------|
| M0                     | No distant metastasis |
| M1                     | Distant metastasis |
| M1a                    | Non-regional lymph node(s) |
| M1b                    | Bone(s) |
| M1c                    | Other sites(s) |
IBM SPSS version 22.0 (IBM Corp. Armonk, NY, USA) was used for statistical analysis of the datasets. Cohen’s kappa (κ) analysis was used to determine the agreement between biopsy and pathology results. The strength of the agreement was evaluated according to κ coefficient (Table 4). In all tests, the statistical significance level was set at 0.05.

3. Results
The mean age of the patients was 60.4 ± 5.7 years (range: 46–78). The mean of the PSA levels was 11.5 ± 7.8 ng/mL (range: 4–54). The mean Gleason score was 6.25 ± 0.97 (range: 4–9) on needle biopsies and 6.69 ± 1.17 (range: 4–10) on pathology specimens (Table 5).

The biopsy results were described as primary and secondary Gleason grades and were compared to the results of the prostatectomy specimens; Gleason grades on biopsies remained identical in 54%, were undergraded in 7%, and overgraded in 39% on prostatectomy specimens. The κ coefficient was calculated as 0.37 in statistical correlation tests (p < 0.01). The primary and secondary Gleason grades of the biopsy revealed a poor prediction of prostatectomy specimens’ primary and secondary Gleason grades.

The biopsy results were defined as the individual Gleason scores and confirmed with prostatectomy specimens’ results. The total Gleason scores of biopsies remained the same in 55%, were undergraded in 9%, and overgraded in 36% on prostatectomy specimens. The κ coefficient was 0.34 in statistical correlation tests (p < 0.01). The individual Gleason score of the biopsy showed a poor prediction of prostatectomy specimens’ individual Gleason scores.

The results were divided into groups according to ISUP 2014 prostate cancer grading system. The biopsies were compared with the groups of prostatectomy specimens, and the groups of biopsies stayed the same in 64%, undergraded in 8%, and overgraded in 28% on groups of prostatectomy specimens. Although the number that remained identical increased, this was not reflected in the accuracy test. The κ coefficient was computed as 0.39 in statistical correlation testing (p < 0.01). The biopsy groups in binary groups had a poor correlation with prostatectomy specimens (Table 6).

4. Discussion
Prostate cancer ranks fourth among cancers worldwide [11]. DRE is a simple and established tool to diagnose prostate cancer [12]. Current methods can provide a cure
Patients with localized prostate cancer who do not have prostatic capsule involvement and have no evidence of metastasis are suitable for radical prostatectomy [14]. However, radical prostatectomy is not performed in every patient with localized prostate cancer [15]. Clinical staging is decisive when planning the treatment of patients with prostate cancer [16]. Depending on the clinical stage, watchful waiting or radiation therapy may also be an alternative [17]. Thus, special efforts have been made for accurate clinical staging. The most important condition of correct clinical staging is that the biopsy results show the pathology results with high accuracy.

The most common mismatch between biopsy and pathology in the literature is the undergrading of biopsy [18]. We found that biopsy samples showed undergrading versus pathology in each evaluation group. In addition, the prostate biopsy does not have sufficient accuracy, which is a common issue in the literature [19]. In the literature, multiparametric prostate MRI and MRI fusion biopsy have higher kappas than conventional prostate biopsy [20,21].

In the literature, studies reporting a weak correlation between biopsy and prostatectomy total Gleason scores are common [22]. We found that the compliance was 55% with weak correlation when the total Gleason score was considered. Similarly, the literature shows discrepancy when the Gleason score was defined as the primary and secondary points [23]. There was 54% agreement and weak correlation consistent with the literature. In our study, the total Gleason scores were classified according to ISUP 2014 prostate cancer grading system, and the agreement was 64% with correlation statistics that showed poor agreement. This result was compatible with the literature [24]. In detail, in the grade 2 group, 54% remained identical, 23% were undergraded, and 23% were overgraded. In grade 3, 60% remained identical, 20% were undergraded, and 20% were overgraded. With a more accurate method, about a quarter of these patients could have been kept under active surveillance and thus could have been protected from the side effects of the treatment if only temporarily.

Accuracy and correlation are important in common malignant disease and staging is important. Our data and the literature suggest that only conventional biopsy is insufficient to predict pathology results. In light of this information, prostate biopsy should not be trusted alone. Considering that there are as many undergraded results as accurate results, treatment planning based on these results alone may not be accurate. We found that prostate biopsy is not so reliable as to ignore alternative methods. Urologists should try to compensate for this limitation by using repeat biopsy, saturation biopsy, and/or MRI-supported biopsy according to the case history and details.

Acknowledgments
We thank all patients who participated in the study and those who carried out the extensive clinical and laboratory work. We would also like to thank Eray Eroğlu M.D. (Nephrologist, State Hospital, Kilis, Turkey) for all his advices and comments during the preparation and revision of the article.

Conflicts of interest
All authors declare that there are no conflicts of interest.

Ethics approval and consent to participate
All procedures performed in human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was conducted under the approval of the Ethical Council of Erciyes University, Faculty of Medicine (13.12.2013 / 98681246-340). Informed consent was obtained from all individual participants included in the study.

Patient consent for publication
All patients gave informed written consent about being a part of this clinical research and publication.

Authors’ contributions
İÜ and ÖOY conceived and designed the study. ÖOY collected the data and İÜ set up the study, analyzed the data and wrote the manuscript. DD provided supervision.
References

1. Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nature Reviews Clinical Oncology 2014; 11: 308-323. doi: 10.1038/nrclinonc.2014.68

2. Bjurlin MA, Taneja SS. Standards for prostate biopsy. Current Opinion in Urology 2014; 24(2): 155-161. doi: 10.1097/MOU.0000000000000031

3. Lepor H. Selecting treatment for high-risk, localized prostate cancer: the case for radical prostatectomy. Reviews in Urology 2002; 4(3): 147-152. PMCID: PMC1475986

4. Khoddami M, Khademi Y, Kazemi Aghdam M, Soltanghorae H. Correlation between Gleason scores in needle biopsy and corresponding radical prostatectomy specimens: a twelve-year review. Iranian Journal of Pathology 2016; 11(2): 120-126. PMID: 27499772 PMCID: PMC4939641

5. Shariat SF, Roehrborn CG. Using biopsy to detect prostate cancer. Reviews in Urology 2008; 10(4): 262-280. PMID: 19145270 PMCID: PMC2615104

6. Overduin CG, Futterer JJ, Barentsz JO. MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results. Current Urology Reports 2013; 14(3): 209-213. doi: 10.1007/s11934-013-0323-z

7. Weiss B, Loeb S. MRI/ultrasound fusion biopsy versus standard 12-core biopsy. Reviews in Urology 2015; 17(2): 113-115. doi: 10.3909/riu0670b

8. Yuasa T, Tsuchiya N, Kumazawa T, Inoue T, Narita S et al. Characterization of prostate cancer detected at repeat biopsy. BMC Urology 2008; 8: 14. doi: 10.1186/1471-2490-8-14

9. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005; 66(2): 356-360. doi: 10.1016/j.urology.2005.03.002

10. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. The American Journal of Surgical Pathology 2016; 40(2): 244-252. doi: 10.1097/PAS.0000000000000530.

11. Rawla P. Epidemiology of prostate cancer. World Journal of Oncology 2019; 10(2): 63-89. doi: 10.14740/wjon1191

12. Akbulut Z, Atmaca AF, Demirci DA, Doğan B, Canda AE et al. What would happen if neurovascular bundles were left behind in radical retropubic prostatectomy? Turkish Journal of Medical Sciences 2103; 43: 448-454. doi: 10.3906/sag-1209-71

13. Jewett MA, Fleschner N, Klotz LH, Nam RK, Trachtenberg J. Radical prostatectomy as treatment for prostate cancer. Canadian Medical Association Journal 2003; 168(1): 44-45. PMID: 12515785 PMCID: PMC139318

14. Lepor H. Selecting candidates for radical prostatectomy. Reviews in Urology 2000; 2(3): 182-189. PMID: 16985772 PMCID: PMC1476131

15. Lepor H. Management of clinically localized prostate cancer. Reviews in Urology 2004; 6 Suppl 2: S3-S12. PMID: 16985859 PMCID: PMC1472856

16. van Wijk Y, Halilaj I, van Limbergen E, Walsh S, Lutgens L et al. Decision Support Systems in Prostate Cancer Treatment: An Overview. Biomed Research International 2019; 2019: 4961768. doi: 10.1155/2019/4961768

17. Westover K, Chen MH, Moul J, Robertson C, Polascik T et al. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. BJU International 2012; 110(8): 1116-1121. doi: 10.1111/j.1464-410X.2012.11012.x

18. Treurniet KM, Trudel D, Sykes J, Evans AJ, Finelli A et al. Downgrading of biopsy based Gleason score in prostatectomy specimens. Journal of Clinical Pathology 2014; 67(4): 313-318. doi: 10.1136/jclinpath-2012-201323

19. Presti JC. Prostate biopsy: current status and limitations. Reviews in Urology 2007; 9(3): 93-98. PMID: 17934565 PMCID: PMC2002498

20. Boesen L. Multiparametric MRI in detection and staging of prostate cancer. Danish Medical Journal 2017; 64(2): B5327. PMID: 28157066

21. Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A et al. Magnetic resonance imaging-transrectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. European Urology 2015; 67(4): 787-794. doi: 10.1016/j.euro.2014.08.077

22. Mills SE, Fowler JE Jr. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer 1986; 57(2): 346-349. doi: 10.1002/1097-0142(19860115)57:2<346::aid-cncr2820570226>3.0.co;2-e

23. Garnett JE, Oyasu R, Grayhack JT. The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason’s classification of radical prostatectomy specimens. Journal of Urology 1984; 131(4): 690-693. doi: 10.1016/s0022-5347(17)50583-2

24. Lattouf JB, Saad F. Gleason score on biopsy: is it reliable for predicting the final grade on pathology? BJU International 2002; 90(7): 694-699. doi: 10.1046/j.1464-410x.2002.02990.x